Advances in the HIF-1α/p300 protein-protein interaction inhibitors

MO Xiaofei; XU Xiaoli; WANG Yalou; YOU Qidong

doi:10.11665/j.issn.1000-5048.20170502

Journal of China Pharmaceutical University > 2017 > 48(5): 515-522. > DOI: 10.11665/j.issn.1000-5048.20170502

MO Xiaofei, XU Xiaoli, WANG Yalou, YOU Qidong. Advances in the HIF-1α/p300 protein-protein interaction inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(5): 515-522. DOI: 10.11665/j.issn.1000-5048.20170502

Citation:

PDF (3733 KB)

Advances in the HIF-1α/p300 protein-protein interaction inhibitors

More Information

Graphical Abstract

Abstract

Abstract

Hypoxia induced factor-1α(HIF-1α)is a key regulation factor that helps tumor adapt itself to the hypoxia microenvironment. It regulates the expression of more than 100 target genes that control cell proliferation and survival, metabolism, angiogenesis, invasion and metastasis. HIF-1α/p300, a core complex that regulates downstream genes expression, is considered as a potential antitumor target. This review summarizes HIF-1α signal pathway, the binding mode of HIF-1α/p300 protein-protein interaction and recent development on the HIF-1α/p300 protein-protein interaction inhibitors, which provides reference to the design of this kind of inhibitors.
- HIF-1α,
- p300,
- protein-protein interaction,
- antitumor,
- progress

FullText(HTML)

References (30)

References

[1]	Harris AL.Hypoxia—a key regulatory factor in tumor growth[J]. Nat Rev Cancer,2002,2(1):38-47.
[2]	Semenza GL.HIF-1:upstream and downstream of cancer metabolism[J]. Curr Opin Genet Dev,2010,20(1):51-56.
[3]	Arany Z,Huang LE,Eckner R,et al.An essential role for p300/CBP in the cellular response to hypoxia[J]. Proc Natl Acad Sci U S A,1996,93(23):12969-12973.
[4]	Kamei Y,Xu L,Heinzel T,et al.A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors[J]. Cell,1996, 85(3):403-414.
[5]	Vo N,Goodman RH.CREB-binding protein and p300 in transcriptional regulation[J]. J Biol Chem,2001,276(17):13505-13508.
[6]	Majmundar AJ,Wong WJ,Simon MC.Hypoxia-inducible factors and the response to hypoxic stress[J]. Mol Cell,2010,40(2):294-309.
[7]	Xia Y,Choi HK,Lee K.Recent advances in hypoxia-inducible factor(HIF)-1 inhibitors[J]. Eur J Med Chem,2012,49:24-40.
[8]	Semenza GL.Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene,2010,29(5):625-634.
[9]	Semenza GL.Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer,2003,3(10):721-732.
[10]	Semenza GL.Hypoxia-inducible factors in physiology and medicine[J]. Cell,2012,148(3):399-408.
[11]	Freedman SJ,Sun ZY,Poy F,et al.Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha[J]. Proc Natl Acad Sci U S A,2002,99(8):5367-5372.
[12]	Shimoda LA, Semenza GL. Functional analysis of the role of hypoxia-inducible factor 1 in the pathogenesis of hypoxic pulmonary hypertension[J]. Methods Enzymol,2004,381(1):121-129.
[13]	Dames SA,Martinezyamout M,De Guzman RN,et al.Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response[J]. Proc Natl Acad Sci U S A,2002,99(8):5271-5276.
[14]	Kyle HF,Wickson KF,Stott J,et al.Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies[J]. Mol Biosyst,2015,11(10):2738-2749.
[15]	Henchey LK, Kushal S, Dubey R, et al. Inhibition of hypoxia inducible factor 1 transcription coactivator interaction by a hydrogen bond surrogate α-helix[J]. J Am Chem Soc,2009,132(3):941-943.
[16]	Kushal S,Lao BB,Henchey LK,et al.Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling[J]. Proc Natl Acad Sci U S A,2013,110(39):15602-15607.
[17]	Burslem GM,Kyle HF,Breeze AL,et al.Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein Interaction[J]. ChemBioChem,2014,15(8):1083-1087
[18]	Lao BB, Grishagin I, Mesallati H, et al. In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics[J]. Proc Natl Acad Sci U S A,2014,111(21):7531-7536.
[19]	Cook KM,Hilton ST,Mecinovi'c J,et al.Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1α(HIF-1α)and p300 by a zinc ejection mechanism[J]. J Biol Chem,2009,284(39):26831-26838.
[20]	Block KM,Wang H,Szabo LZ,et al.Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine[J]. J Am Chem Soc,2009,131(50):18078-18088.
[21]	Reece KM,Richardson ED,Cook KM,et al.Epidithiodiketopiperazines(ETPs)exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer[J]. Mol Cancer,2014,13(1):91.
[22]	Jayatunga MK,Thompson S,McKee TC,et al.Inhibition of the HIF1α-p300 interaction by quinone-and indandione-mediated ejection of structural Zn(II)[J]. Eur J Med Chem,2015, 94:509-516.
[23]	Na YR,Han KC,Park H,et al.Menadione and ethacrynic acid inhibit the hypoxia-inducible factor(HIF)pathway by disrupting HIF-1α interaction with p300[J]. Biochem Biophys Res Commun,2013,434(4):879-884.
[24]	Wu D,Zhang R,Zhao R,et al.A novel function of novobiocin:disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF-1α C-terminal activation domain[J]. PLoS ONE,2013,8(5):e62014.
[25]	Kwon HS,Kim DR,Yang EG,et al.Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1α-p300 interaction by a small molecule[J]. Bioorg Med Chem Lett,2012,22(16):5249-5252.
[26]	Mooring SR,Jin H,Devi NS,et al.Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway[J]. J Med Chem,2011,54(24):8471-8489.
[27]	Mun J,Jabbar AA,Devi NS,et al.Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl] heteroarylsulfonamides,novel,small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents[J]. J Med Chem,2012,55(15):6738-6750.
[28]	Shi Q,Yin S,Kaluz S,et al.Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor[J]. ACS Med Chem Letters,2012,3(8):620-625.
[29]	Wang W,Ao L,Rayburn ER,et al.KCN1,a novel synthetic sulfonamide anticancer agent:in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology[J]. PLoS ONE,2012,7(9):e44883.
[30]	Liu F,Sun HP,You QD.Advances in small-molecule inhibitor targeting Hsp 90-Cdc37 protein-protein interaction[J].J China Pharm Univ(中国药科大学学报),2015,46(3):272-278.

[1]	SHEN Yunhong, CHEN Hongjie, MAO Zewei, HUANG Zhengxiao, HU Chunyan. Synthesis and antifungal evaluation of chalcone derivatives combined with fluconazole against drug-resistant Candida albicans[J]. Journal of China Pharmaceutical University, 2023, 54(5): 564-568. DOI: 10.11665/j.issn.1000-5048.2023041002
[2]	Gao Zhonghao. 新型药物递送系统技术在药物研发中的应用和展望[J]. Journal of China Pharmaceutical University, 2023, 54(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2023030303
[3]	YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
[4]	BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
[5]	SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
[6]	JIA Chengshu, WANG Junwei, LI Hui, ZHU Qihua, GE Yiran, XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528. DOI: 10.11665/j.issn.1000-5048.20170503
[7]	CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
[8]	JIANG Yuqiu, TANG Qiaofei, ZHANG Shuang, YAN Zhiyong. Combined effects of gallic acid and ciprofloxacin on the murine chronic rhinosinusitis model in mice[J]. Journal of China Pharmaceutical University, 2015, 46(5): 600-604. DOI: 10.11665/j.issn.1000-5048.20150514
[9]	HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC_20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
[10]	WU Keqin. Antitumor activity and mechanism of saikosaponin D combined with oxaliplatin on A549 cells-bearing nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(3): 355-358. DOI: 10.11665/j.issn.1000-5048.20150316

Cited By

Cited by

Periodical cited type(2)

1.	任红梅，熊晔蓉，荀校莹，姜雷，涂家生. 新型含铝疫苗佐剂的研究进展. 中国药科大学学报. 2025(02): 236-243 . 本站查看
2.	袁明城，张剑，陈洋，薛潘，武福星，袁若栋，董阳超，徐志凯，张芳琳，雷迎峰. 仙台病毒递送新型冠状病毒RBD蛋白鼻内免疫接种增强呼吸道黏膜和系统性免疫应答的初步研究. 空军军医大学学报. 2023(07): 609-614 .

Other cited types(1)

Get Citation

PDF

XML

Article views (1163) PDF downloads (2676) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Advances in the HIF-1α/p300 protein-protein interaction inhibitors

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Advances in the HIF-1α/p300 protein-protein interaction inhibitors

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Export File

Citation

Format

Content